Table 2.
In vitro characterization of studied Zr-89 labelled siderophores. Log P, protein binding (expressed as % of protein bound activity of the total activity used) and stability (in human serum and 6 mM DTPA) of [89Zr]TAFC, [89Zr]FOXE, [89Zr]FCHA and [89Zr]FOXB
| [89Zr]siderophore | Log P (mean ± SD, n = 6) | Incubation time (min) | Protein binding (%) (mean, n = 2) | Stability in human serum (%) (n = 1) | Stability in DTPA solution (%) (n = 1) |
|---|---|---|---|---|---|
| [89Zr]TAFC | −1.95 ± 0.03 | 1 | 0.99 | 98.08 | 99.51 |
| 4 | 0.34 | 98.72 | 99.50 | ||
| 24 | 1.37 | 98.50 | 99.50 | ||
| [89Zr]FOXE | −1.91 ± 0.04 | 1 | 3.27 | 98.07 | 99.70 |
| 4 | 5.86 | 99.70 | 99.50 | ||
| 24 | 16.59 | 98.34 | 99.70 | ||
| [89Zr]FCHA | −3.28 ± 0.37 | 1 | 2.70 | 92.76 | 68.70 |
| 4 | 6.24 | 85.42 | 65.27 | ||
| 24 | 31.05 | 77.38 | 54.22 | ||
| [89Zr]FOXB | −3.01 ± 0.07 | 1 | 1.63 | 99.61 | 91.56 |
| 4 | 2.05 | 99.70 | 90.39 | ||
| 24 | 1.84 | 99.53 | 87.10 |